Direct Ora

Circulation

Volumn 135, Issue 7, 2017, Pages 714-716

  Siontis, Konstantinos C ^a   Yao, Xiaoxi ^b   Gersh, Bernard J ^a   Noseworthy, Peter A ^a  

^a MAYO CLINIC   (United States)

^b Department of Health Sciences Research ^*  (United States)

Author keywords

anticoagulant; atrial fibrillation; meta analysis; valve

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANNULOPLASTY; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; ATRIAL FIBRILLATION; COCHRANE LIBRARY; DISEASE SEVERITY; EMBASE; HUMAN; MECHANICAL HEART VALVE; MEDLINE; META ANALYSIS; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRICUSPID VALVE STENOSIS; VALVULAR HEART DISEASE; VALVULOPLASTY; FEMALE; HEART VALVE PROSTHESIS; MALE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; MALE;

EID: 85012925403     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.026793     Document Type: Article

References (5)

1. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624-632. doi: 10. 1161/CIRCULATIONAHA. 114. 014807.
2. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016;134:589-598. doi: 10. 1161/CIRCULATIONAHA. 115. 020950.
3. Renda G, De Caterina R, Carnicelli A, Nordio F, Mercuri M, Ruff C, Giugliano R. Outcomes in 2824 patients with valvular heart disease treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2016;67:2194-2194 (abstract).
4. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35:3377-3385. doi: 10. 1093/eurheartj/ ehu305.
5. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Califf RM, Fox KA, Patel MR; ROCKET AF Steering Committee & investigators. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102:1036-1043. doi: 10. 1136/ heartjnl-2015-308120.